Nachrichten der Wirtschaftskanzleien
Westinghouse Electric Company Files for Chapter 11
Student Athlete Class Action Against UNC Chapel Hill Dismissed
El Pollo Loco Secures Second Dismissal of Securities Complaint
AXA Equitable Wins New SLUSA Dismissal of Variable Annuity Case
Intellectually Disabled Client Granted Relief by Supreme Court
National CinemaChain Sells Cinema Park
Parrot Automotive and Faurecia Form Partnership
Nippon Shokubai to Acquire Sirrus
Gumi to Establish Joint Venture With Nordisk Film
DuPont/Dow Merger Approved by EU
China-Based AirMedia Secures Dismissal of Class Action Complaint
Skadden Named International Arbitration Team of the Year
Sealed Air to Sell New Diversey to Bain Capital Private Equity
French State to Sell Interest in Peugeot
Former CFTC General Counsel Jonathan L. Marcus Joins Skadden as Of Counsel
Olswang advises two new VC clients on Series B investment round in British biotech Pulmocide
International technology, media and telecoms law firm Olswang has advised venture capital firms SR One Ltd and Longwood Fund III LP for the first time, on their Series B round of investment of Pulmocide Limited, a biotech developing two treatments for deadly viral and fungal lung infections.
The $30 million (£24 million) cash injection is Pulmocide's second, having already secured $17 million in an initial fundraising round. In addition to SR One and Longwood Fund, the fresh funds come from Pulmocide's existing backers including venture capital firm SV Life Sciences, J&J DC, the venture capital arm of Johnson & Johnson, Touchstone Innovations and F-prime, the venture capital arm of Fidelity.
Olswang Corporate Partner Niall McAlister commented: "It was a pleasure to advise SR One and Longwood Fund III on their investment in Pulmocide. This significant investment follows Pulmocide's strong track record of clinical success and these monies will go a long way to developing two critical treatments currently being developed – one for babies with Respiratory Syncytial Virus and the other for fungal infection Aspergillosis."
Niall McAlister led the transaction along with IP Partner and Head of Life Sciences Robert Stephen, Corporate Senior Associate Kate Blumhof, IP Associate Hemma Lad, Share Schemes Legal Director Catherine Merry and Trainee Alex Lowe.
Read more about Olswang’s international legal practice on the firm’s website.
(ENDS)
